Developing practical recommendations for drug-disease interactions in patients with hypertension
Frontiers in Pharmacology · 17.04.2024 · 15
DOI: 10.3389/fphar.2024.1360146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.04.2024. Verfasst von Kübra Özokcu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Meander Medisch Centrum, Amersfoort, Netherlands. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hypertension, a significant risk factor for cardiovascular diseases, demands proactive management as cardiovascular diseases remain the leading cause of death worldwide. Reducing systolic and diastolic blood pressure levels below recommended reference values of <140/90 mmHg can lead to a significant reduction of the risk of CVD and all-cause mortality. However, treatment of hypertension can be difficult and the presence of comorbidities could further complicate this treatment. Drugs used to manage these comorbidities may inadvertently have an impact on blood pressure, resulting in a phenomenon known as drug-disease interaction. This study aims to assess the safety of medication that can affect blood pressure in patients with hypertension and provide practical recommendations for healthcare professionals.
Methods
For the development of recommendations for the drug-disease interaction (DDSI) hypertension, a six-step plan that combined literature selection and multidisciplinary expert opinion was used. The process involved (1) defining the scope of the DDSI and selecting relevant drugs, (2) collecting evidence, (3) data-extraction, (4) reaching of expert consensus, (5) publication and implementation of the recommendations in healthcare systems and (6) updating the information.
Results
An increase of 10 mmHg in systolic blood pressure and 5 mmHg in diastolic blood pressure was defined as clinically relevant. Corticosteroids, danazol, and yohimbine caused a clinically relevant DDSI with hypertension. Several other drugs with warnings for hypertension in the official product information were assessed to have no clinically relevant DDSI due to minor influence or lack of data on blood pressure. Drugs with evidence for a relevant change in blood pressure which are prescribed under close monitoring of blood pressure according to clinical guidelines, were deemed to be not clinically relevant for signalling.
Conclusion
This study provides specific recommendations that can be implemented directly in clinical practice, for example, in clinical decision support systems, potentially resulting in safer drug use in patients with hypertension and better healthcare by reducing alert fatigue. Future research should focus on evaluating the effectiveness of implementation strategies and their impact on reducing unsafe use of medication in patients with hypertension.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hospital Pharmacy, Meander Medisch Centrum, Amersfoort, Netherlands.
- Department of Hospital Pharmacy, Ziekenhuis Rivierenland, Tiel, Netherlands.
- Department of Clinical Decision Support, Health Base Foundation, Houten, Netherlands.
- Medicines Information Centre, Royal Dutch Pharmacists Association (KNMP), The Hague, Netherlands.
- Department of Hospital Pharmacy, Maasstad Hospital, Rotterdam, Netherlands.
- Departments of Internal Medicine and Public Health Amsterdam Cardiovascular Sciences Amsterdam UMC, Amsterdam, Netherlands.
Zitieren
APA
Özokcu, K., Diesveld, M. M. E., Gipmans, S. G. H., Peeters, L. E. J., van den Born, B. J., & Borgsteede, S. D. (2024). Developing practical recommendations for drug-disease interactions in patients with hypertension. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1360146
Vancouver
Özokcu K, Diesveld MME, Gipmans SGH, Peeters LEJ, van den Born BJ, Borgsteede SD. Developing practical recommendations for drug-disease interactions in patients with hypertension. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1360146
BibTeX
@article{zokcu2024,
author = {Özokcu, Kübra and Diesveld, Maaike M E and Gipmans, Suzan G H and Peeters, Laura E J and van den Born, Bert-Jan and Borgsteede, Sander D},
title = {Developing practical recommendations for drug-disease interactions in patients with hypertension},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1360146}
}
EUVIMED